Extensive organizing pneumonia during chemo-immunotherapy containing rituximab and G-CSF in a patient with diffuse large B-cell lymphoma: Case report and review of the literature [6]

Leukemia and Lymphoma

Volumn 47, Issue 8, 2006, Pages 1683-1685

  Mian, M ^a   Rass, C ^a   Hutarew, G ^a   Kofler, B ^a   Fiegl, M ^b   Greil, R ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ADULT; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CANCER STAGING; CASE REPORT; DISEASE SEVERITY; DRUG FEVER; HUMAN; INFECTIOUS PNEUMONIA; LARGE CELL LYMPHOMA; LETTER; LUNG INFILTRATE; MALE; MEDICAL LITERATURE; MYCOSIS; NEUTROPENIA; ORGANIZING PNEUMONIA; PRIORITY JOURNAL; TONGUE CANCER;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; LYMPHOMA, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; PNEUMONIA;

EID: 33748569810     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600612586     Document Type: Letter

References (15)

1. Pfreundschuh, M and Trumper, L and Ma, D and Osterborg, A and Pattengell, R and Trneny, M and (2004) Randomized intergroup trial of first line treatment for patients ≤60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab -early stopping after the first interim analysis J Clin Oncol, 22(14 suppl), pp. 6500. (Meeting Abstracts)
2. Sehn, L and Donaldson, J and Chhanabhai, M and Fizgerald, C and Gill, K and Klasa, R and (2005) Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia J Clin Oncol, 23(22), pp. 5027-5033.
3. McLaughlin, P and Grillo-Lopez, A and Link, B and Levy, R and Czuczman, M and Williams, M and (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program J Clin Oncol, 16(8), pp. 2825-2833.
4. Alexandrescu, D and Dutcher, J and O'Boyle, K and Albulak, M and Oiseth, S and Wiernik, P. (2004) Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma Leuk Lymphoma, 45(11), pp. 2321-2325.
5. Swords, R and Power, D and Fay, M and O'Donnell, R and Murphy, P. (2004) Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP) Am J Hematol, 77(1), pp. 103-104.
6. Leon, R and Gonsalvo, A and Salas, R and Hidalgo, N. (2004) Rituximab-induced acute pulmonary fibrosis Mayo Clin Proc, 79(7), pp. 949-953.
7. Burton, C and Kaczmarski, R and Jan-Mohamed, R. (2003) Interstitial pneumonitis related to rituximab therapy N Engl J Med, 348(26), pp. 2690-2691.
8. Hiraga, J and Kondoh, Y and Taniguchi, H and Kinoshita, T and Naoe, T. (2005) A case of interstitial pneumonia induced by rituximab therapy Int J Hematol, 81(2), pp. 169-170.
9. Law, L and Tuscano, J and Wun, T and Ahlberg, K and Richman, C. (2002) Filgrastim treatment of acute myelogenous leukemia (M7) relapse after allogeneic peripheral stem cell transplantation resulting in both graft-versus-leukemia effect with cytogenetic remission and chronic graft-versus-host disease manifesting as polyserositis and subsequent bronchiolitis obliterans with organizing pneumonia Int J Hematol, 76(4), pp. 360-364.
10. Meyer, R and Gyger, M and Langley, R and Lesperance, B and Caplan, S. (1998) A phase I trial of standard and cyclophosphamide dose-escalated CHOP with granulocyte colony stimulating factor in elderly patients with non-Hodgkin's lymphoma Leuk Lymphoma, 30(5-6), pp. 591-600.
11. Hasegawa, Y and Ninomiya, H and Kamoshita, M and Ohtani, K and Kobayashi, T and Kojima, H and (1997) Interstitial pneumonitis related to granulocyte colony-stimulating factor administration following chemotherapy for elderly patients with non-Hodgkin's lymphoma Intern Med, 36(5), pp. 360-364.
12. Pfreundschuh, M and Trumper, L and Kloess, M and Schmits, R and Feller, A and Rudolph, C and (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL Blood, 104(3), pp. 626-633.
13. Kanelli, S and Ansell, S and Habermann, T and Inwards, D and Tuinstra, N and Witzig, T. (2001) Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis Leuk Lymphoma, 42(6), pp. 1329-1337.
14. Byrd, J and Gribben, J and Peterson, B and Grever, M and Lozanski, G and Lucas, D and (2005) Select High-Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy With Fludarabine and Rituximab in Chronic Lymphocytic Leukemia: Justification for Risk-Adapted Therapy J Clin Oncol, 24, pp. 437-443.
15. Hainsworth, J and Litchy, S and Lamb, M and Rodriguez, G and Scroggin, C, Jr and Greco, F. (2003) First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: Phase II trial Clin Lymphoma, 4(1), pp. 36-42.